Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 114Neoplasms 37Neoplasm Metastasis 24Stomach Neoplasms 22Pancreatic Neoplasms 19Colonic Neoplasms 15Rectal Neoplasms 13Esophageal Squamous Cell Carcinoma 13Sarcoma 10Esophageal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Small Cell Lung Carcinoma 8Sarcoma, Ewing 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Ovarian Neoplasms 6Gastrointestinal Neoplasms 6Uterine Cervical Neoplasms 5Solid Tumors 5Recurrence 5Neuroblastoma 5Intestinal Neoplasms 5Digestive System Neoplasms 5Cholangiocarcinoma 5Advanced Solid Tumor 5Rhabdomyosarcoma 4Gastrointestinal Diseases 4Endometrial Neoplasms 4Digestive System Diseases 4

Interventions

Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cirrhosis, Familial, with Pulmonary Hypertension × Irinotecan × Clear all
NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

TransThera Sciences (Nanjing), Inc.

Phase 3 Not yet recruiting
138 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡